Welcome to our dedicated page for VivoSim Labs news (Ticker: VIVS), a resource for investors and traders seeking the latest updates and insights on VivoSim Labs stock.
VivoSim Labs, Inc. (Nasdaq: VIVS) is a pharmaceutical and biotechnology services company that focuses on testing drugs and drug candidates in three-dimensional human tissue models of liver and intestine. This news page aggregates coverage of the company’s announcements, scientific presentations and corporate developments related to its NAMkind platform and toxicology services.
Readers can find updates on leadership changes, such as the appointment of a Chief Commercial Officer to guide go‑to‑market strategy and partnerships, and the appointment of a Chief Scientific Officer to oversee scientific strategy across toxicology, translational models, bioanalytics and next‑generation new approach methodologies. News items also highlight how VivoSim Labs combines organ‑specific 3D models with AI‑driven analytics to deliver what it describes as decision‑ready toxicology insights.
Company news includes reports of scientific results, such as presentations at conferences where VivoSim Labs has discussed the predictive performance of its NAMkind liver model against challenging liver toxicity cases. These articles describe sensitivity and specificity metrics within test sets of compounds and explain how the platform is intended to address unforeseen liver toxicity that can emerge in clinical trials or after market launch.
In addition, news releases from VivoSim Labs discuss its emergence from stealth mode, its focus on non‑animal NAM methods in the context of FDA initiatives to refine animal testing requirements, and its view of the market opportunity for liver and gastrointestinal in vitro models and toxicology services. Investors, scientists and industry professionals can use this page to follow how the company communicates its progress in AI‑enabled liver and intestine toxicology, regulatory context and corporate governance milestones over time.
VivoSim (Nasdaq: VIVS) appointed Dr. Arumugham (Ragoo) Raghunathan as Vice President of Global Sales, effective March 3, 2026, to lead commercial expansion from the Greater Boston area and deepen East Coast engagement. The hire targets growth in liver and GI toxicity NAM services, strategic partnerships, and scaled deployments across biopharma, CROs, and research institutions.
Dr. Raghunathan will focus on earlier de‑risking of drug candidates, advancing pilot-to-scale customer programs, and accelerating adoption of human-relevant liver and GI toxicity solutions.
VivoSim (Nasdaq: VIVS) will present validation data for its NAMkind™ liver and NAMkind™ intestine models at the Society of Toxicology meeting in San Diego, March 22-25, 2026. Testing versus marketed antibody drug conjugates (ADCs) reportedly shows close correlation with clinical liver toxicity and intestinal side effects (diarrhea).
VivoSim says these human 3D models can reveal target engagement, premature linker cleavage, and bystander effects, and its NAMkind toxicology services are available in the US, Europe, Korea and China as capacity scales.
VivoSim Labs (Nasdaq: VIVS) appointed JCBio in Korea and Tekon Biotech in China as authorized distributors for its NAMKind™ human-based liver and small-intestine toxicology services, expanding Asia-Pacific commercial access.
The services target faster, human-relevant screening with a targeted 30-day turnaround per compound and address rising regional demand for New Approach Methodologies.
VivoSim Labs (Nasdaq: VIVS) appointed Amar Sethi, M.D., Ph.D. as Chief Scientific Officer effective January 6, 2026. Dr. Sethi brings roughly three decades of drug-development, biomarker, CRO, and translational-medicine experience and will lead scientific strategy across toxicology, translational models, bioanalytics, and next-generation NAMs on VivoSim’s NAMkind platform.
His background includes leading global Phase I–IV programs, FDA breakthrough and orphan-designation work, BLA experience, establishing CAP/CLIA/GCP/GLP-compliant infrastructures, and advancing biomarker platforms—including an FDA-qualified Acute Kidney Injury panel. VivoSim said he will expand biomarker capabilities, strengthen scientific governance for sponsors, and collaborate with R&D, platform engineering, and AI teams to improve multi-parametric toxicity prediction.
VivoSim Labs (NASDAQ:VIVS) has appointed Tony Lialin as Chief Commercial Officer to scale its AI-enabled NAMkind™ liver and intestine toxicology services. The company operates in the $641M global liver and gastrointestinal in-vitro models and toxicology services market, with services representing 53.1% of revenue.
The U.S. accounts for $325M (50.8%) of the global liver toxicology market, with the in vitro liver model segment growing at a 5.9% CAGR from 2020-2024. VivoSim Labs combines 3D human tissue models with AI analytics to deliver early-stage toxicology insights for pharmaceutical development, capitalizing on increasing adoption of non-animal testing methodologies supported by FDA Modernization Act 2.0.
VivoSim Labs (Nasdaq: VIVS) has emerged from stealth mode to revolutionize drug development with its NAMkind™ services suite, following FDA's announcement to phase out animal testing requirements. The company's technology focuses on liver and intestinal toxicology using human organ model-based lab testing and AI-powered computational modeling.
The company aims to disrupt the $10B+ animal testing market with more predictive and ethically sound methods. VivoSim's liver model has demonstrated industry-best correlation rates with known clinical failures, and the company projects it can reduce clinical trial failures due to liver toxicity by 50% or more.
The technology utilizes physical organoid wet lab models created from human donor cells, combined with AI-driven predictions for liver toxicity, intestinal toxicity, and permeability. VivoSim believes its approach could reduce drug development costs per approved drug by 50% across the industry.